PRICE HISTORY.
Use the left and right arrow keys to inspect dated observations. Home selects the first observation and End selects the latest.
Key numbers
Published fundamentals and the date each figure was recorded.
Veeda Lifesciences is a global contract research organisation that supplies clinical, preclinical and bioanalytical services to drug-development clients. Its issuer website says the business supports innovative, biosimilar and generic drugs. The cited service scope includes preclinical R&D, bioequivalence and bioavailability studies, bioanalytical work and early- to late-phase clinical trials from Phase I through Phase IV. Veeda says it operates across multiple regions and works with clients during drug-development programs rather than selling therapeutic products. Its stated operating focus is scientific research execution, regulatory compliance and ethical practices, supported by investment in people, processes and technology. The company describes its mission as delivering science-based, technology-led and client-specific solutions, with execution capabilities across geographies. Its website also identifies real-world data and AI as tools it intends to use in supporting development programs. This description excludes promotional performance claims and forward-looking estimates.
About this company
Veeda Clinical Research Limited is an India-based contract research organisation (CRO) incorporated in 2004 and headquartered in Ahmedabad, Gujarat. The company provides end-to-end clinical research services to the pharmaceutical and biotechnology industry, spanning bioavailability and bioequivalence (BA/BE) studies, pre-clinical testing, early and late-phase clinical trials, bioanalytical work, pharmacovigilance, and medical writing. Veeda operates research facilities across Ahmedabad, Mehsana, and Bangalore, and has expanded through acquisitions including a stake in Bioneeds and the European CRO Heads, alongside a biosimilars joint venture. According to publicly available information, it has served clients across multiple countries and reports completing global regulatory inspections by authorities such as the USFDA. The company has filed a draft red herring prospectus (DRHP) with SEBI as part of a proposed public listing. As an unlisted, pre-IPO security, its shares carry higher risk, limited price transparency, and significantly lower liquidity than listed equities, and valuations can change sharply. This page is for information only and is not investment advice.
COMPANY REGISTRY · ON FILE
THE CREW · BOARD & MANAGEMENT
COMMON QUESTIONS.
Is Veeda Clinical Research Limited listed on the stock exchange?+
No. As of 2 September 2026, Veeda Clinical Research Limited is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
What is the Veeda Clinical Research Limited unlisted share price?+
As of 2 September 2026, the indicative unlisted share price of Veeda Clinical Research Limited is ₹428 per share. This is an over-the-counter reference price, not a stock-exchange quote.
What indicative minimum amount is displayed for Veeda Clinical Research Limited unlisted shares?+
The displayed unit count is 25 share(s); at the indicative price of about ₹428, the displayed amount is approximately ₹10,700. This is a display convention, not evidence of inventory, an order minimum or a quote.
What is the ISIN of Veeda Clinical Research Limited?+
The recorded ISIN of Veeda Clinical Research Limited is INE01HQ01026. An ISIN is a 12-character security identifier. Verify it against the issuer and the relevant depository record before using it for any transfer or documentation.
Is trading in Veeda Clinical Research Limited unlisted shares legal in India?+
Unlisted shares can be transferred off-market in India, but the legal, tax and compliance position depends on the security, parties, documents and current rules. Verify the intermediary, issuer restrictions and applicable requirements before proceeding.
Is there a lock-in period for unlisted shares?+
A post-listing lock-in may apply under the rules in force at the time. The period and any exemptions can depend on the holder and acquisition, so check the current regulation and the issuer's offer documents rather than relying on a generic period.
Do you guarantee returns?+
No. Unlisted shares carry higher risk and lower liquidity than listed shares. Returns depend on company performance, market conditions and future listing outcomes. This is information only, not investment advice.